Abstract Background. In 2012/2013, a single dose of 13-valent pneumococcal conjugate
vaccine (PCV13) was recommended for immunocompromised adults in the United States …

Background Newly diagnosed HIV-positive individuals are 35 to 100-fold more susceptible
to Streptococcus pneumoniae infection compared to non-infected individuals. Therefore, the …

Nasopharyngeal colonization with Streptococcus pneumoniae precedes invasive
pneumococcal disease. Human immunodeficiency virus (HIV) infection increases rates of …

Objectives: To assess the feasibility of establishing a pneumococcal vaccine trial among HIV-
1-infected adults in Uganda and to characterize their responses to 23-valent pneumococcal …

The objective of this study was to assess the factors implicated in an increased or decreased
risk of pneumonia, with particular attention to the response to highly active antiretroviral …

Background Pneumocystis pneumonia (PCP) remains a leading cause of morbidity and
mortality in HIV-infected persons. Epidemiology of PCP in the recent era of highly active …

To assess the impact of vaccination with 23-valent pneumococcal polysaccharide vaccine
on the risks for development of pneumococcal disease, all-cause community-acquired …

Background: In developed countries with free access to health care, primary
chemoprophylaxis with co-trimoxazole, and antiretroviral treatment, Pneumocystis …

Objective: To assess the factors that increase or decrease the risk of pneumonia with
particular attention to immunization with pneumococcal and influenza vaccines in a group of …

Background. Polysaccharide pneumococcal vaccine (PPV) is recommended among human
immunodeficiency virus (HIV)–infected patients, although its effect in reducing the incidence …